Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 26B1 (CYP26B1) is a monooxygenase enzyme that catalyzes the hydroxylation and inactivation of all-trans-retinoic acid, playing a crucial role in retinoid homeostasis. It is essential for proper skeletal, limb, and lymphatic system development. Dysregulation of CYP26B1 is implicated in limb malformations, lymphedema, and certain cancers like colorectal cancer.
Inhibitors of CYP26B1 would increase retinoic acid levels; activators would decrease retinoic acid levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 family 26 subfamily B member 1 (CYP26B1).